Literature DB >> 11781193

Immunoexpressions of p21, Rb, mcl-1 and bad gene products in normal, hyperplastic and carcinomatous human prostates.

M Royuela1, M I Arenas, F R Bethencourt, M Sánchez-Chapado, B Fraile, R Paniagua.   

Abstract

A comparative study of the expression of p21, Rb, mcl-1, and bad gene products, which are involved in the control of the cell cycle, was performed in normal, hyperplastic, and carcinomatous human prostates by means of a semiquantitative immunochemical study. This included Western blot, ELISA, and immunohistochemistry procedures. In normal prostates, immunoexpression of the four gene products was scanty or absent. In men with benign prostatic hyperplasia, immunoreactions to the four proteins studied were found in many epithelial cells and some stromal cells. In prostatic carcinoma, the immunostaining pattern was as in hyperplastic prostates but the numbers of both epithelial and stromal cells were higher. Present results indicate that immunoexpression of p21, Rb (both the phosphorylated and dephosphorylated forms), mcl-1, and bad gene products are markedly increased in prostates with proliferative alterations but that these proteins do not discriminate between benignant (hyperplasia) and malignant (adenocarcinoma) prostatic tumours, although immunoexpression is higher in prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781193

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  8 in total

1.  The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.

Authors:  Rui Huang; Xue-Qin Chen; Ying Huang; Ni Chen; Hao Zeng
Journal:  Asian J Androl       Date:  2010-05-17       Impact factor: 3.285

2.  Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats.

Authors:  Bianca Facchim Gonçalves; Silvana Gisele Pegorin de Campos; Wagner José Fávaro; Joyce Zalotti Brandt; Cristiane Figueiredo Pinho; Luis Antônio Justulin; Sebastião Roberto Taboga; Wellerson Rodrigo Scarano
Journal:  Horm Cancer       Date:  2018-01-23       Impact factor: 3.869

Review 3.  MicroRNAs as putative mediators of treatment response in prostate cancer.

Authors:  Fardod O'Kelly; Laure Marignol; Armelle Meunier; Thomas H Lynch; Antoinette S Perry; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2012-05-22       Impact factor: 14.432

4.  Expression of the Bcl-2 protein BAD promotes prostate cancer growth.

Authors:  Adrienne J Smith; Yelena Karpova; Ralph D'Agostino; Mark Willingham; George Kulik
Journal:  PLoS One       Date:  2009-07-13       Impact factor: 3.240

5.  Behavioral stress accelerates prostate cancer development in mice.

Authors:  Sazzad Hassan; Yelena Karpova; Daniele Baiz; Dana Yancey; Ashok Pullikuth; Anabel Flores; Thomas Register; J Mark Cline; Ralph D'Agostino; Nika Danial; Sandeep Robert Datta; George Kulik
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

6.  Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Veit Sandfort; Sanjeewani T Palayoor; Barbara H Rath; Lance Liotta; Mariaelena Pierobon; Emanuel F Petricoin; Matthew F Brown; Jayne M Stommel; Mansoor M Ahmed; C Norman Coleman
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.009

7.  Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.

Authors:  Francesco Fabbri; Giovanni Brigliadori; Silvia Carloni; Paola Ulivi; Ivan Vannini; Anna Tesei; Rosella Silvestrini; Dino Amadori; Wainer Zoli
Journal:  J Transl Med       Date:  2008-08-08       Impact factor: 5.531

8.  Angiotensin 1-7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer.

Authors:  Kamila Domińska; Piotr Okła; Karolina Kowalska; Dominika Ewa Habrowska-Górczyńska; Kinga Anna Urbanek; Tomasz Ochędalski; Agnieszka Wanda Piastowska-Ciesielska
Journal:  Sci Rep       Date:  2018-10-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.